Comparative Pharmacology
Head-to-head clinical analysis: APIDRA SOLOSTAR versus HUMALOG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APIDRA SOLOSTAR versus HUMALOG.
APIDRA SOLOSTAR vs HUMALOG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin glulisine is a recombinant human insulin analog that lowers blood glucose by binding to insulin receptors on muscle and fat cells, facilitating glucose uptake, and inhibiting hepatic glucose production.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by binding to insulin receptors on skeletal muscle and adipocytes, leading to increased glucose uptake and reduced hepatic glucose production.
Subcutaneous injection, 0.2-0.4 units/kg/day divided into two or more doses; for basal-bolus therapy, total daily dose is 0.5-1.0 units/kg/day with 50-60% as prandial insulin glulisine.
Subcutaneous injection: 0.2-1.0 units/kg/day divided into 3 or more doses, given within 15 minutes before or immediately after a meal. Typical total daily dose range 0.5-1.0 units/kg/day.
None Documented
None Documented
1.0-1.5 hours (terminal elimination half-life; consistent with rapid absorption and clearance; shorter than regular human insulin)
Subcutaneous: 0.5-1.0 hour (insulin lispro); longer with renal impairment (up to 1.5-3 hours).
Renal: 60-80% of dose as metabolites and parent drug; biliary/fecal: minor (20-40%)
Renal: 60-80% as unchanged drug; biliary/fecal: minor (<10%).
Category C
Category C
Insulin
Insulin